Sustained protection against both hepatitis A and hepatitis B
Twinrix Adult is a vaccine for use in adults and adolescents over 16 years of age and above; Twinrix Paediatric is a vaccine for use in non- immune infants, children and adolescents from 1 year up to and including 15 years. It is used to prevent 2 diseases: hepatitis A and hepatitis B. 12A combined vaccine reduces the number of injections needed, offering the benefits of increased compliance and reduced costs. 34The vaccine works by causing the body to produce its own protection (antibodies) against both diseases. 12
- Twinrix Adult has been shown to cause an immune memory response with higher and continuous antibodies against HBV in adults over 40 years compared to other single-strain vaccines 6
- Twinrix Paediatric has been shown to induce long-term antibody persistence for up to 10 years following initial vaccination in children aged 12–15 years and for 5 years in children aged 1–11 years 2 7 8
- Twinrix Adult Summary of Product Characteristics, GlaxoSmithKline.
- Twinrix Paediatric Summary of Product Characteristics, GlaxoSmithKline
- Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Exp Rev Vaccines 2004;3:249–267.
- Murdoch GL, Goa K, Figgitt DP. Combined Hepatitis A and B Vaccines: A Review of Their Immunogenicity and Tolerability. Drugs 2003;63:2625–2649.
- Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008;26:1759–1763.
- Chlibek R, von Sonnenburg F, Van Damme P, et al. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. J Travel Med 2011;18:145–148.
- Beran J, Kervyn D, Wertzova V, et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine 2010;28:5993–5997.
- Leder K, Chen L. Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis. Vaccine 2012;30:2600–2604.